Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Amazon Posts Solid Earnings. A Cloud Miss and Weak Outlook Are Hurting the Stock.
Fourth-quarter results beat Wall Street estimates but the company’s revenue outlook for the first quarter fell shy of ...
KNSI Radio18h
St. Cloud School District Sets Special Election to Fill Resigned Board Member’s Seat
(KNSI) - The St. Cloud Area Public School District has set a special election to fill the term of a board member who resigned ...